Ofranergene obadenovec

奥巴-奥雷呐近

Report date: 2026/03/11 20:02:12

Base Information

Drug NameOfranergene obadenovec
Drug Alias NameOfranergenum obadenovecumofra-vecGT-111VB-111
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAV5 vector
Mechanisms of ActionVascular disrupting agents (VDA)Angiogenesis modulatorsGene expression modulators +[5] 
TargetsFatty acid synthaseTumor necrosis factor receptor superfamily member 1A
Therapy Area/IndicationsOvarian NeoplasmsColorectal NeoplasmsThyroid Carcinoma, Anaplastic +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesPoland +[6] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesVascular Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesVascular Biogenics Ltd. Operating As Vbl TherapeuticsNanocarrier Co Ltd
Inactive CompaniesDana-Farber Cancer InstituteNational Cancer Institute
Active IndicationsOvarian Neoplasms
Inactive IndicationsColorectal NeoplasmsThyroid Carcinoma, AnaplasticNeuroendocrine Tumors +[5] 

Other Information

ATC CodeN/A
Related LinksN/A